Fig. 2From: Long non‐coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancerNORAD promoted bone metastasis of PCa cells in vitro by inhibiting miR-541-3p a, Representative images of FISH with NORAD probe (in red) and DAPI (in blue) in PCa cells (× 400). b, Binding site of NORAD and miR-541-3p predicted by StarBase. c, The expression of miR-541-3p in PCa tissues detected by PCR. d, Dual luciferase assay showed the interaction between NORAD and miR-541-3p, ** p < 0.01 vs. HEK293T cells transfected with miR-541-3p mimic NC. e, qRT-PCR showed the effect of NORAD on miR-541-3p expression in PCa cells, ** p < 0.01 vs. PC-3 cells treated with sh-NC or 22Rv1 cells treated with vector. f, qRT-PCR showed NORAD and miR-541-3p expression after treatment with sh-NORAD and miR-541-3p inhibitor, * p < 0.05, ** p < 0.01 vs. PC-3 cells treated with sh-NC + inhibitor NC or 22Rv1 treated with vector + mimic NC; # p < 0.05, ## p < 0.05 vs. PC-3 cells treated with sh-NORAD + inhibitor NC or 22Rv1 treated with OE-NORAD + mimic NC. g, Transwell showing the effect of NORAD and miR-541-3p on the migration of PCa cells towards HS-5-CM, * p < 0.05, ** p < 0.01 vs. PC-3 cells treated with sh-NC + inhibitor NC or 22Rv1 treated with vector + mimic NC; # p < 0.05, ## p < 0.05 vs. PC-3 cells treated with sh-NORAD + inhibitor NC or 22Rv1 treated with OE-NORAD + mimic NC. The measurement data were expressed as mean ± standard deviation. Unpaired t-test was used for comparison between two groups. ANOVA was used for comparison between multiple groups with Tukey’s post-hoc test. The cell experiment was repeated 3 timesBack to article page